Bernstein Initiates Coverage On Gilead Sciences with Outperform Rating, Announces Price Target of $105

Benzinga · 10/17 11:38
Bernstein analyst Aaron Gal initiates coverage on Gilead Sciences (NASDAQ:GILD) with a Outperform rating and announces Price Target of $105.